Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 7

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 7
---
 associated with Highbridge Capital Management LLC providing for the issuance and sale, in a registered direct offering, or the November 2024 Registered Direct Offering, of 16,471,449 ADSs (or pre-funded warrants to purchase ADSs in lieu of ADSs). Each ADS and pre-funded warrant was sold together with a number of warrants equal to 50% of the aggregate number of ADSs and pre-funded warrants sold in the November 2024 Registered Direct Offering, or in total ordinary warrants to purchase up to an aggregate of 8,235,724 ADSs, at a combined purchase price of $0.5464 per ADS and accompanying ordinary warrant and $0.5463 per pre-funded warrant and accompanying ordinary warrant. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per ADS, subject to adjustment as set forth therein, and will not expire until exercised in full. The ordinary warrants have an exercise price of $0.5900 per ADS, subject to adjustment as set forth therein, are immediately exercisable, and have a 4-year term from the issuance date. Aggregate gross proceeds from the November 2024 Registered Direct Offering (without taking into account any proceeds from any future exercises of warrants) was $9.0 million. The November 2024 Registered Direct Offering closed on November 21, 2024. Our Corporate Information Our principal executive offices are located at 2 HaMa’ayan Street, Modi’in 7177871, Israel, and our telephone number is +972 (8) 642-9100. Our wholly owned subsidiary, BioLineRx USA, Inc., was incorporated in Delaware on January 4, 2008, and is located at 77 Fourth Ave, Waltham, Massachusetts 02451. Our website is www.biolinerx.com. The reference to our website is an inactive textual reference only and the information contained in, or that can be accessed through, our website or any other website cited in this prospectus supplement or the accompanying prospectus is not a part of this prospectus supplement or the accompanying prospectus. S - 2 THE OFFERING

| Issuer                                                      |     | BioLineRx Ltd.                                                                                                                                                                                                                                     |
| ADSs offered by us                                          |     | 34,332,122 ADSs representing 514,981,830 ordinary shares.                                                                                                                                                                                          |
| Pre-funded warrants offered by us                           |     | Pre-funded warrants to purchase up to an aggregate of 15,667,878